AMRN - Amarin Corporation plc Stock Trading

Amarin (NASDAQ: AMRN ) is scheduled to announce Q2 earnings results on Tuesday, August 4th, before market open. The consensus EPS Estimate is -$0.07  vs. $0.02 in 2Q19 and the consensus Revenue Estimate is $149.48M (+48.3% Y/Y). Over the last 2 years, AMRN has beaten EPS esti...

What luck has gave you will probably leave you ."― Amit Kalantri I have had a couple of requests to revisit this name. A full investment analysis is as follows. The stock also continues to look like a good covered call candidate at current trading levels. The stock has formed a sol...

New data from the REDUCE-IT clinical trial (REVASC analysis) presented at the American Society for Preventive Cardiology Virtual Summit on CVD Prevention showed that the administration of 4 g/day of Amarin's (NASDAQ: AMRN ) Vascepa (icosapent ethyl) resulted in a 34% reduction in first ...